NIKKEI 225
38,299.71 +25.66 (+0.07%) HANG SENG
18,143.21 +380.18 (+2.14%) CRUDE OIL
79.46 +0.46 (+0.58%) GOLD FUTURES
2,328.50 +17.50 (+0.76%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,896.78 -2,057.57 (-4.29%)
DNLI Sep 2024 17.500 call
| Previous close | 2.8000 |
| Open | 2.8000 |
| Bid | 0.8500 |
| Ask | 4.6000 |
| Strike | 17.50 |
| Expiry date | 2024-09-20 |
| Day's range | 2.8000 - 2.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
GlobeNewswireDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which
Simply Wall St.Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.74 Denali...
ZacksWhy Denali Therapeutics (DNLI) Stock Might be a Great Pick
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
